Navigation Links
CRH Medical reports Q2 2008 results
Date:8/28/2008


- Revenues increase 138% versus Q2 2007

- Nine new Centers opened to date in 2008

VANCOUVER, Aug. 28 /PRNewswire-FirstCall/ - CRH Medical Corporation (CRM:TSX-V) announced today unaudited results for the three and six months ended June 30, 2008 (all figures are in US dollars). Revenue for the three months ended June 30, 2008 increased 138% to $1,653,891 compared to $695,994 for the same period in 2007. Revenue for the six months ended June 30, 2008 increased 150% to $3,001,333 compared to $1,202,048 for the same period in 2007. The Company recorded a net loss of $1,097,973 ($0.02 per share) and $2,056,711 ($0.05 per share) for the three and six months ended June 30, 2008 compared to a net loss of $773,785 ($0.02 per share) and $1,950,824 ($0.05 per share) for the same periods in 2007. Additionally, the Company announced that as of June 30, 2008 it had $1.976 million in cash and cash equivalents and working capital of $2.986 million.

The Company also announced that for the three months ended June 30, 2008, it had 6,496 patient visits at its Centers for Colorectal Health compared to 2,859 patient visits for the same period in 2007.

Commenting on the second quarter, 2008 results, Edward Wright, Chief Executive Officer stated, "The addition of nine new centers opened to date in 2008 continues to demonstrate our ability to expand the Centers for Colorectal Health network. Additionally our direct to physician initiative, whereby we provide training and support for physicians purchasing our technology, is garnering strong momentum. These two strategies enable greater accessibility to our technology and treatment protocols which we expect will provide significant revenue growth."

Summary of interim results (expressed in United States dollars):

Consolidated Balance Sheet

-------------------------------------------------------------------------

Jun
'/>"/>

SOURCE CRH Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Frost & Sullivan Honours Redsense Medical With the 2008 European Hemodialysis Emerging Company of the Year Award
2. Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director
3. ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association
4. University Hospitals Case Medical Center recognized by American Heart Association
5. Shaping Best Practices For Standardized Medical Imaging In Clinical Trials
6. NitiBrite™ - Break-through in Nitinol Wire Product for Medical Devices
7. Medical Records Institute Unveils Platform for Studying Cell Phone Applications in Healthcare
8. Hartwell Medical Announces Release of CombiCarrierII Scoop Backboard to EMS Market
9. Greenway Medical Technologies Growth Continues with Significant Fiscal Year 2008 Gains
10. First Major Medical Meeting Convening for MRI-guided Focused Ultrasound to Treat Cancer, Stroke, Fibroids, Other Conditions
11. iCan Benefit Group, LLC Announces: Major Medical Division Now Offers Avalon Healthcare Products
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6JumpStart Invests in Checkpoint Surgical 6118 1JumpStart Invests in Checkpoint Surgical 6118 2JumpStart Invests in Checkpoint Surgical 6118 3Some chest pain patients wait longer than 10 minutes to see ER physician 61033 1Some chest pain patients wait longer than 10 minutes to see ER physician 61033 2Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 1Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast 6115 2
Other Medicine Technology:Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9Video: Actress and New Mom Keri Russell Joins PKIDs to Launch 'Silence the Sounds of Pertussis' Campaign 2Video: Actress and New Mom Keri Russell Joins PKIDs to Launch 'Silence the Sounds of Pertussis' Campaign 3